Recently, “SCLC-I” subtype, which is characterized by low expression of ASCL1, NEUROD1, and POU2F3 accompanied by an inflammatory gene signature, is considered to obtain the greatest benefit from immunochemotherapy10,11. The gene discussed is POU2F3; the disease is small cell lung carcinoma.